Cargando…

Fluorescent, Plasmonic, and Radiotherapeutic Properties of the (177)Lu–Dendrimer-AuNP–Folate–Bombesin Nanoprobe Located Inside Cancer Cells

The integration of fluorescence and plasmonic properties into one molecule is of importance in developing multifunctional imaging and therapy nanoprobes. The aim of this research was to evaluate the fluorescent properties and the plasmonic–photothermal, therapeutic, and radiotherapeutic potential of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mendoza-Nava, Héctor, Ferro-Flores, Guillermina, Ramírez, Flor de María, Ocampo-García, Blanca, Santos-Cuevas, Clara, Azorín-Vega, Erika, Jiménez-Mancilla, Nallely, Luna-Gutiérrez, Myrna, Isaac-Olivé, Keila
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5469519/ https://www.ncbi.nlm.nih.gov/pubmed/28654384 http://dx.doi.org/10.1177/1536012117704768

Ejemplares similares

Theoretical and experimental characterization of emission and transmission spectra of Cerenkov radiation generated by (177)Lu in tissue
por: Jiménez-Mancilla, Nallely P., et al.
Publicado: (2019)

(177)Lu-DOTA-HYNIC-Lys(Nal)-Urea-Glu: Biokinetics, Dosimetry, and Evaluation in Patients with Advanced Prostate Cancer
por: Santos-Cuevas, Clara, et al.
Publicado: (2018)

[(177)Lu]Lu-PSMA-617 (Pluvicto(TM)): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer
por: Hennrich, Ute, et al.
Publicado: (2022)

Synthesis and Evaluation of (177)Lu-DOTA-PD-L1-i and (225)Ac-HEHA-PD-L1-i as Potential Radiopharmaceuticals for Tumor Microenvironment-Targeted Radiotherapy
por: Luna-Gutiérrez, Myrna, et al.
Publicado: (2023)

Fabrication and Verification of Conjugated AuNP-Antibody Nanoprobe for Sensitivity Improvement in Electrochemical Biosensors
por: Khashayar, Patricia, et al.
Publicado: (2017)

Preclinical Evaluation of a New Series of Albumin-Binding (177)Lu-Labeled PSMA-Based Low-Molecular-Weight Radiotherapeutics
por: Boinapally, Srikanth, et al.
Publicado: (2023)

Improving Overall Survival and Quality of Life in Patients with Prostate Cancer and Neuroendocrine Tumors Using (177)Lu-iPSMA and (177)Lu-DOTATOC: Experience after 905 Treatment Doses
por: Luna-Gutiérrez, Myrna, et al.
Publicado: (2023)

Intraindividual comparison of [(177)Lu]Lu-DOTA-EB-TATE and [(177)Lu]Lu-DOTA-TOC
por: Hänscheid, Heribert, et al.
Publicado: (2021)

AuNP Aptasensor for Hodgkin Lymphoma Monitoring
por: Slyusarenko, Maria, et al.
Publicado: (2022)

PEGylation, increasing specific activity and multiple dosing as strategies to improve the risk-benefit profile of targeted radionuclide therapy with (177)Lu-DOTA-bombesin analogues
por: Däpp, Simone, et al.
Publicado: (2012)

Crystalline AuNP-Decorated Strontium Niobate Thin Films: Strain-Controlled AuNP Morphologies and Optical Properties for Plasmonic Applications
por: Yao, Qiaomu, et al.
Publicado: (2023)

Practical kidney dosimetry in peptide receptor radionuclide therapy using [(177)Lu]Lu-DOTATOC and [(177)Lu]Lu-DOTATATE with focus on uncertainty estimates
por: Staanum, Peter Frøhlich, et al.
Publicado: (2021)

First-In-Human Results on the Biodistribution, Pharmacokinetics, and Dosimetry of [(177)Lu]Lu-DOTA.SA.FAPi and [(177)Lu]Lu-DOTAGA.(SA.FAPi)(2)
por: Ballal, Sanjana, et al.
Publicado: (2021)

Matched-pair analysis of [(177)Lu]Lu-PSMA I&T and [(177)Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
por: Hartrampf, Philipp E., et al.
Publicado: (2022)

Kidney absorbed radiation doses for [(177)Lu]Lu-PSMA-617 and [(177)Lu]Lu-PSMA-I&T determined by 3D clinical dosimetry
por: Uijen, Maike J.M., et al.
Publicado: (2023)

Evaluation of the (177m)Lu-concentration in in-house produced (177)Lu-radiopharmaceuticals and commercially available Lutathera(®)
por: Balzer, Matthias, et al.
Publicado: (2023)

Influence of sampling schedules on [(177)Lu]Lu-PSMA dosimetry
por: Rinscheid, Andreas, et al.
Publicado: (2020)

Extravasation of [(177)Lu]Lu-DOTATOC: case report and discussion
por: Arveschoug, Anne Kirstine, et al.
Publicado: (2020)

Improved quality control of [(177)Lu]Lu-PSMA I&T
por: Kraihammer, Martin, et al.
Publicado: (2023)

Urinary excretion kinetics of [(177)Lu]Lu-PSMA-617
por: de Bakker, Maarten, et al.
Publicado: (2023)

Absorbed dose assessment of (177)Lu-zoledronate and (177)Lu-EDTMP for human based on biodistribution data in rats
por: Yousefnia, Hassan, et al.
Publicado: (2015)

Distinct In Vitro Binding Profile of the Somatostatin Receptor Subtype 2 Antagonist [(177)Lu]Lu-OPS201 Compared to the Agonist [(177)Lu]Lu-DOTA-TATE
por: Mansi, Rosalba, et al.
Publicado: (2021)

Imageable AuNP-ECM Hydrogel Tissue Implants for Regenerative Medicine
por: Shilo, Malka, et al.
Publicado: (2023)

Synthesis and Evaluation of (177)Lu-DOTA-DN(PTX)-BN for Selective and Concomitant Radio and Drug—Therapeutic Effect on Breast Cancer Cells
por: Gibbens-Bandala, Brenda, et al.
Publicado: (2019)

Radionuclide generator-based production of therapeutic (177)Lu from its long-lived isomer (177m)Lu
por: Bhardwaj, Rupali, et al.
Publicado: (2019)

Development of (177)Lu-phytate Complex for Radiosynovectomy
por: Yousefnia, Hassan, et al.
Publicado: (2013)

Lutetium Lu-177 Dotatate Flare Reaction
por: Salner, Andrew L., et al.
Publicado: (2020)

Inter-comparison of quantitative imaging of lutetium-177 ((177)Lu) in European hospitals
por: Wevrett, Jill, et al.
Publicado: (2018)

Toxicity Assessment of [(177)Lu]Lu−iFAP/iPSMA Nanoparticles Prepared under GMP-Compliant Radiopharmaceutical Processes
por: Hernández-Jiménez, Tania, et al.
Publicado: (2022)

Design of a scalable AuNP catalyst system for plasmon-driven photocatalysis
por: Stolle, Heike Lisa Kerstin Stephanie, et al.
Publicado: (2018)

Systematic and mechanistic analysis of AuNP-induced nanotoxicity for risk assessment of nanomedicine
por: Lee, Euiyeon, et al.
Publicado: (2022)

Plasmon-exciton couplings in the MoS(2)/AuNP plasmonic hybrid structure
por: Kim, Hyuntae, et al.
Publicado: (2022)

Passive Sampling of Gaseous Elemental Mercury Based on a Composite TiO(2)NP/AuNP Layer
por: Macagnano, Antonella, et al.
Publicado: (2018)

Joint EANM/SNMMI procedure guideline for the use of (177)Lu-labeled PSMA-targeted radioligand-therapy ((177)Lu-PSMA-RLT)
por: Kratochwil, Clemens, et al.
Publicado: (2023)

Cure of Disseminated Human Lymphoma with [(177)Lu]Lu-Ofatumumab in a Preclinical Model
por: Shim, Kyuhwan, et al.
Publicado: (2023)

Individualisation of radiation protection recommendations for patients treated with [(177)Lu]Lu-DOTA-TATE
por: Monserrat Fuertes, Teresa, et al.
Publicado: (2023)

Production of 177Lu with deuterons at IFMIF-DONES facility
por: López-Melero, Elena, et al.
Publicado: (2021)

Preparation and evaluation of Lu-(177) phytate Complex for Radiosynovectomy
por: Yousefnia, Hassan, et al.
Publicado: (2014)

Nephrotoxicity after PRRT with (177)Lu-DOTA-octreotate
por: Bergsma, Hendrik, et al.
Publicado: (2016)

Lutetium Lu 177 Vipivotide Tetraxetan: First Approval
por: Keam, Susan J.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qq4219l22v3v07gvvteqkrn7e0